quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·53d
PRRelease
Monopar Therapeutics Inc. logo

Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

MNPR· Monopar Therapeutics Inc.
Health Care
Original source

Companies

  • MNPR
    Monopar Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 9UpdateMorgan Stanley$115.00
  • Nov 14UpdateRaymond James-
  • Nov 10UpdateLeerink Partners$115.00
  • Oct 13UpdateBarclays$125.00
  • Sep 9UpdateBTIG Research$87.00
  • Sep 3UpdateOppenheimer$77.00

Related

  • SEC4d
    Monopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR4d
    Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
  • INSIDER21d
    SEC Form 4 filed by Robinson Chandler
  • INSIDER21d
    SEC Form 4 filed by Cittadine Andrew
  • SEC22d
    Amendment: SEC Form 10-K/A filed by Monopar Therapeutics Inc.
  • SEC27d
    Monopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC27d
    SEC Form 10-K filed by Monopar Therapeutics Inc.
  • PR27d
    Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022